“The problem with the Alzheimer’s group is they were very co-opted,” said Peter J. Whitehouse, MD, PhD, a professor of ...

Prolonged rapid eye movement (REM) sleep latency was linked with Alzheimer's disease biomarkers, cross-sectional data showed.

350 mg/20 mL every four weeks injection for IV infusion), Eli Lilly and Company's (NYSE: LLY) Alzheimer's treatment for adults with early symptomatic Alzheimer's disease, which includes people ...

A new study led by Western researchers found frequent treatment with intranasal oxytocin – a hormone in the brain associated ...

The drug received standard U.S. approval in 2023 after showing it slowed cognitive decline in patients with the brain-wasting ...

Japanese pharmaceutical company Eisai Co and U.S. firm Biogen Inc said Monday that a jointly developed Alzheimer's drug has been approved for continuous use for people with early stages of the disease ...

Eleven drugs are poised to reach blockbuster status, dramatically improving patient outcomes on a global scale.

Eli Lilly and Company (NYSE:LLY), a leading pharmaceutical giant with a market capitalization of $724 billion, has been ...

Leerink Partners analyst David Risinger has reiterated their bullish stance on BMY stock, giving a Buy rating on January 12.Invest with ...

Eli Lilly has chalked up another regulatory approval for its anti-amyloid therapy for Alzheimer's disease, Kisunla, in China – the world's second-largest pharma market. The National Medical ...

Biogen BIIB announced that the FDA has approved a monthly maintenance dosing version for its intravenously (IV) administered ...

Eli Lilly and Company (NYSE:LLY) develops, manufactures, discovers, and sells pharmaceutical products. These products span ...